aspartic acid has been researched along with Parkinsonian Disorders in 10 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As lesions associated with Guadeloupean parkinsonism are poorly characterized, it is not known to what extent they differ from progressive supranuclear palsy." | 1.36 | Magnetic resonance imaging lesion pattern in Guadeloupean parkinsonism is distinct from progressive supranuclear palsy. ( Bienaimée, MJ; Delmaire, C; Galanaud, D; Gaymard, B; Hartmann, A; Jodoin, N; Lannuzel, A; Lehéricy, S; Roze, E; Vidailhet, M, 2010) |
| "A 9-year-old girl with akinetic-rigid parkinsonism with tremor is described." | 1.33 | Epilepsy, parkinsonism, and neuroleptic malignant syndrome in a child. ( Cantú-Martínez, L; Flores, Lde L; González, HC; Martínez, HR; Onofre-Castillo, J; Villarreal, HJ, 2006) |
| "Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations." | 1.32 | Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, W | 1 |
| Zheng, Z | 1 |
| Zhuang, W | 1 |
| Chen, D | 1 |
| Wang, X | 2 |
| Sun, X | 1 |
| Lehéricy, S | 1 |
| Hartmann, A | 1 |
| Lannuzel, A | 1 |
| Galanaud, D | 1 |
| Delmaire, C | 1 |
| Bienaimée, MJ | 1 |
| Jodoin, N | 1 |
| Roze, E | 1 |
| Gaymard, B | 1 |
| Vidailhet, M | 1 |
| Tan, Y | 1 |
| Yu, F | 1 |
| Pereira, A | 1 |
| Morin, P | 1 |
| Zhou, J | 1 |
| Zietlow, R | 1 |
| Sinclair, SR | 1 |
| Schwiening, CJ | 1 |
| Dunnett, SB | 1 |
| Fawcettt, JW | 1 |
| Podell, M | 1 |
| Hadjiconstantinou, M | 1 |
| Smith, MA | 1 |
| Neff, NH | 1 |
| Boska, MD | 1 |
| Lewis, TB | 1 |
| Destache, CJ | 1 |
| Benner, EJ | 1 |
| Nelson, JA | 1 |
| Uberti, M | 1 |
| Mosley, RL | 1 |
| Gendelman, HE | 1 |
| Leutenegger, AL | 1 |
| Salih, MA | 1 |
| Ibáñez, P | 1 |
| Mukhtar, MM | 1 |
| Lesage, S | 1 |
| Arabi, A | 1 |
| Lohmann, E | 1 |
| Dürr, A | 1 |
| Ahmed, AE | 1 |
| Brice, A | 1 |
| Martínez, HR | 1 |
| Cantú-Martínez, L | 1 |
| González, HC | 1 |
| Flores, Lde L | 1 |
| Villarreal, HJ | 1 |
| Onofre-Castillo, J | 1 |
| van Vliet, SA | 1 |
| van Vlieta, SA | 1 |
| Blezer, EL | 1 |
| Jongsma, MJ | 1 |
| Vanwersch, RA | 1 |
| Olivier, B | 1 |
| Philippens, IH | 1 |
| Federico, F | 1 |
| Simone, IL | 1 |
| Lucivero, V | 1 |
| Mezzapesa, DM | 1 |
| de Mari, M | 1 |
| Lamberti, P | 1 |
| Petruzzellis, M | 1 |
| Ferrari, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Parkin Mutations and Their Functional Consequences[NCT00136721] | 2,500 participants | Observational | 2002-06-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 other studies available for aspartic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
Neural metabolite changes in corpus striatum after rat multipotent mesenchymal stem cells transplanted in hemiparkinsonian rats by magnetic resonance spectroscopy.
Topics: Animals; Aspartic Acid; Cell Differentiation; Cell Survival; Choline; Corpus Striatum; Creatine; Dis | 2013 |
Magnetic resonance imaging lesion pattern in Guadeloupean parkinsonism is distinct from progressive supranuclear palsy.
Topics: Aged; Aspartic Acid; Brain; Case-Control Studies; Cognition Disorders; Creatinine; Diagnosis, Differ | 2010 |
Suppression of Nrdp1 toxicity by Parkin in Drosophila models.
Topics: Amino Acid Substitution; Animals; Animals, Genetically Modified; Aspartic Acid; Cell Survival; Disea | 2011 |
The release of excitatory amino acids, dopamine, and potassium following transplantation of embryonic mesencephalic dopaminergic grafts to the rat striatum, and their effects on dopaminergic neuronal survival in vitro.
Topics: Animals; Aspartic Acid; Cell Death; Corpus Striatum; Dopamine; Excitatory Amino Acids; Extracellular | 2002 |
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S | 2003 |
Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease.
Topics: Adoptive Transfer; Animals; Aspartic Acid; Cell Count; Chromatography, High Pressure Liquid; Corpus | 2005 |
Juvenile-onset Parkinsonism as a result of the first mutation in the adenosine triphosphate orientation domain of PINK1.
Topics: Adenosine Triphosphate; Adolescent; Adult; Age of Onset; Alanine; Amino Acid Sequence; Aspartic Acid | 2006 |
Epilepsy, parkinsonism, and neuroleptic malignant syndrome in a child.
Topics: Anticonvulsants; Antiparkinson Agents; Aspartic Acid; Basal Ganglia; Benzothiazoles; Carbamazepine; | 2006 |
Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Benzhydryl Compounds; Biomarke | 2008 |
Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes.
Topics: Adult; Aged; Aspartic Acid; Brain; Choline; Creatine; Diagnosis, Differential; Disease Progression; | 1999 |